首页> Blood: The Journal of the American Society of Hematology> Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic Syndromes (MDS): Outcomes from the Randomized, Double-Blind Telesto Study

Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic Syndromes (MDS): Outcomes from the Randomized, Double-Blind Telesto Study

导出原文传递

翻译打印收藏纠错

第一作者： Angelucci, Emanuele

作者： Angelucci, Emanuele ^[1] ; Li, Junmin ^[2] ; Greenberg, Peter L. ^[3] ; Depei, Wu ^[4] ; Hou, Ming ^[5] ; Figueroa, Efreen Montano ^[6] ; Rodriguez, Guadalupe ^[7] ; Dong, Xunwei ^[8] ; Ghosh, Jagannath ^[9] ; Bornstein, Orna ; Garcia-Manero, Guillermo

作者单位： IRCCS Osped Policlin San Martino, Hematol & Transplant Ctr, Genoa, Italy ^[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA ^[2] Shandong Univ, Qilu Hosp, Dept Hematol, Jinan, Shandong, Peoples R China ^[3] Stanford Univ, Canc Ctr, Stanford, CA 94305 USA ^[4] Hosp Gen Mexico City, Dept Hematol, Mexico City, DF, Mexico ^[5] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai, Peoples R China ^[6] IMSS, Ctr Med Nacl La Raza, Hosp Especialidades, Dept Hematol, Mexico City, DF, Mexico ^[7] Novartis Pharmaceut, E Hanover, NJ USA ^[8] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Suzhou, Jiangsu, Peoples R China ^[9]

发布时间 2020-08-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交